Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Balazs, A. West (2012)
Antibody gene transfer for HIV immunoprophylaxisNature Immunology, 14
J. Siliciano, R. Siliciano (2014)
Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1.The Journal of allergy and clinical immunology, 134 1
G. Sgouros, D. Goldenberg (2014)
Radiopharmaceutical therapy in the era of precision medicine.European journal of cancer, 50 13
B. Lichty, C. Breitbach, D. Stojdl, J. Bell (2014)
Going viral with cancer immunotherapyNature Reviews Cancer, 14
P. Polakis (2016)
Antibody Drug Conjugates for Cancer TherapyPharmacological Reviews, 68
J. Wiesch, J. Lunzen (2011)
Hide and seek... Can we eradicate HIV by treatment intensificationThe Journal of Infectious Diseases, 203
A. Chung, G. Alter (2014)
Dissecting the antibody constant region protective immune parameters in HIV infectionFuture Virology, 9
A. Balazs, Joyce Chen, C. Hong, D. Rao, Lili Yang, D. Baltimore (2011)
Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxisNature, 481
N. Archin, J. Sung, C. Garrido, N. Soriano-Sarabia, D. Margolis (2014)
Eradicating HIV-1 infection: seeking to clear a persistent pathogenNature Reviews Microbiology, 12
Irene Guijarro-Muñoz, M. Compte, L. Álvarez-Vallina, L. Sanz (2013)
Antibody gene therapy: getting closer to clinical application?Current gene therapy, 13 4
D. Tsukrov, E. Dadachova (2014)
The potential of radioimmunotherapy as a new hope for HIV patientsExpert Review of Clinical Immunology, 10
Z. Ni, D. Knorr, L. Bendzick, J. Allred, D. Kaufman (2014)
Expression of Chimeric Receptor CD4ζ by Natural Killer Cells Derived from Human Pluripotent Stem Cells Improves In Vitro Activity but Does Not Enhance Suppression of HIV Infection In VivoSTEM CELLS, 32
D. Persaud, H. Gay, C. Ziemniak, Y. Chen, M. Piatak, T. Chun, M. Strain, D. Richman, K. Luzuriaga (2013)
Absence of detectable HIV-1 viremia after treatment cessation in an infant.The New England journal of medicine, 369 19
Angel Varela-Rohena, P. Molloy, S. Dunn, Yi Li, M. Suhoski, R. Carroll, A. Milicic, T. Mahon, Deborah Sutton, Bruno Laugel, R. Moysey, Brian Cameron, A. Vuidepot, M. Purbhoo, D. Cole, R. Phillips, C. June, B. Jakobsen, A. Sewell, J. Riley (2008)
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptorNature Medicine, 14
S. Lam, C. Bollard (2013)
T-cell therapies for HIV.Immunotherapy, 5 4
A. Balazs, Y. Ouyang, C. Hong, Joyce Chen, Steven Nguyen, D. Rao, Dong An, David Baltimore (2012)
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmissionRetrovirology, 9
R. Walker, C. Bechtel, V. Natarajan, M. Baseler, K. Hege, J. Metcalf, R. Stevens, A. Hazen, R. Blaese, Clara Chen, S. Leitman, J. Palensky, J. Wittes, R. Davey, J. Falloon, M. Polis, J. Kovacs, D. Broad, B. Levine, M. Roberts, H. Masur, H. Lane (2000)
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.Blood, 96 2
H. Goldstein, M. Pettoello‐Mantovani, T. Bera, I. Pastan, E. Berger (2000)
Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice.The Journal of infectious diseases, 181 3
E. Connick, Teresa Mattila, J. Folkvord, R. Schlichtemeier, Amie Meditz, M. Ray, M. McCarter, S. MaWhinney, Aaron Hage, C. White, P. Skinner (2007)
CTL Fail to Accumulate at Sites of HIV-1 Replication in Lymphoid Tissue12The Journal of Immunology, 178
Rujuta Mehendale, M. Joshi, V. Patravale (2013)
Nanomedicines for treatment of viral diseases.Critical reviews in therapeutic drug carrier systems, 30 1
Bruce Schnepp, Philip Johnson (2014)
Adeno-associated virus delivery of broadly neutralizing antibodiesCurrent Opinion in HIV and AIDS, 9
M. Maus, A. Haas, G. Beatty, S. Albelda, B. Levine, Xiaojun Liu, Yangbing Zhao, M. Kalos, C. June (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in HumansCancer Immunology Research, 1
B. Autran, B. Descours, V. Avettand-Fenoel, C. Rouzioux (2011)
Elite controllers as a model of functional cureCurrent Opinion in HIV and AIDS, 6
J. Whitney, A. Hill, Srisowmya Sanisetty, P. Penaloza-MacMaster, Jinyan Liu, Mayuri Shetty, Lily Parenteau, Crystal Cabral, Jennifer Shields, S. Blackmore, Jeffrey Smith, Amanda Brinkman, L. Peter, Sheeba Mathew, Kaitlin Smith, E. Borducchi, Daniel Rosenbloom, M. Lewis, J. Hattersley, Bei Li, J. Hesselgesser, R. Geleziunas, M. Robb, Jerome Kim, N. Michael, D. Barouch (2014)
Rapid Seeding of the Viral Reservoir Prior to SIV Viremia in Rhesus MonkeysNature, 512
A. McDermott, R. Koup (2012)
CD8+ T cells in preventing HIV infection and diseaseAIDS, 26
Philip Johnson, Bruce Schnepp, Jianchao Zhang, M. Connell, Sean Greene, E. Yuste, R. Desrosiers, Reed Clark (2009)
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeysNature medicine, 15
J. Bakema, M. Egmond (2014)
Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.Current topics in microbiology and immunology, 382
J. Scholler, Troy Brady, G. Binder-Scholl, W. Hwang, G. Plesa, K. Hege, Ashley Vogel, M. Kalos, J. Riley, S. Deeks, R. Mitsuyasu, W. Bernstein, N. Aronson, B. Levine, F. Bushman, C. June (2012)
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T CellsScience Translational Medicine, 4
F. Fay, C. Scott (2011)
Antibody-targeted nanoparticles for cancer therapy.Immunotherapy, 3 3
Wenhai Liu, M. Onda, Byungkook Lee, R. Kreitman, R. Hassan, Laiman Xiang, I. Pastan (2012)
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesProceedings of the National Academy of Sciences, 109
G. Sahu, Kaori Sango, N. Selliah, Q. Ma, G. Skowron, R. Junghans (2013)
Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.Virology, 446 1-2
E. Fritsch, Todd Carter, Eric Lander, Catherine Wu, M. Maus, A. Haas, G. Beatty, S. Albelda, B. Levine, M. Kalos, John Engelhardt, Karla Henning, Mohan Srinivasan, A. Korman (2013)
Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
R. Gilabert-Oriol, A. Weng, Benedicta Mallinckrodt, M. Melzig, H. Fuchs, M. Thakur (2014)
Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific EfficacyCurrent Pharmaceutical Design, 20
A. Wayne, D. FitzGerald, R. Kreitman, I. Pastan (2014)
Immunotoxins for leukemia.Blood, 123 16
J. Brenchley, T. Schacker, Laura Ruff, D. Price, Jodie Taylor, G. Beilman, P. Nguyen, A. Khoruts, Matthew Larson, A. Haase, D. Douek (2004)
CD4+ T Cell Depletion during all Stages of HIV Disease Occurs Predominantly in the Gastrointestinal TractThe Journal of Experimental Medicine, 200
E. Wonderlich, J. Leonard, K. Collins (2011)
HIV immune evasion disruption of antigen presentation by the HIV Nef protein.Advances in virus research, 80
N. Bitton, F. Verrier, P. Debré, G. Gorochov (1998)
Characterization of T cell‐expressed chimeric receptors with antibody‐type specificity for the CD4 binding site of HIV‐1 gp120European Journal of Immunology, 28
A. MacLean, Edith Walker, G. Sahu, G. Skowron, P. Marx, D. Laer, R. Junghans, S. Braun (2014)
A novel real‐time CTL assay to measure designer T‐cell function against HIV Env+ cellsJournal of Medical Primatology, 43
E. Berger (2011)
Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirsCurrent Opinion in HIV and AIDS, 6
S. Kitchen, B. Levin, G. Bristol, V. Rezek, Sohn Kim, C. Aguilera-Sandoval, A. Balamurugan, O. Yang, J. Zack (2012)
In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem CellsPLoS Pathogens, 8
E. Berger, I. Pastan (2010)
Immunotoxin Complementation of HAART to Deplete Persisting HIV-Infected Cell ReservoirsPLoS Pathogens, 6
S. Lewin, S. Deeks, F. Barré-Sinoussi (2014)
Towards a cure for HIV—are we making progress?The Lancet, 384
J. Hong, Praveen Amancha, Kenneth Rogers, A. Ansari, F. Villinger (2012)
Spatial Alterations between CD4+ T Follicular Helper, B, and CD8+ T Cells during Simian Immunodeficiency Virus Infection: T/B Cell Homeostasis, Activation, and Potential Mechanism for Viral EscapeThe Journal of Immunology, 188
R. Mitsuyasu (2013)
Curing HIV: lessons from cancer therapyCurrent Opinion in HIV and AIDS, 8
S. Frankel, P. Baeuerle (2013)
Targeting T cells to tumor cells using bispecific antibodies.Current opinion in chemical biology, 17 3
J. Ananworanich, A. Fauci (2015)
HIV cure research: a formidable challengeJournal of Virus Eradication, 1
M. Roberts, L. Qin, D. Zhang, D. Smith, A. Tran, T. Dull, J. Groopman, D. Capon, R. Byrn, M. Finer (1994)
Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.Blood, 84 9
G. Hütter, D. Nowak, M. Mossner, S. Ganepola, A. Müssig, Kristina Allers, T. Schneider, J. Hofmann, C. Kücherer, O. Blau, I. Blau, W. Hofmann, E. Thiel (2009)
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.The New England journal of medicine, 360 7
E. Connick, J. Folkvord, Katherine Lind, E. Rakasz, B. Miles, N. Wilson, M. Santiago, Kimberly Schmitt, E. Stephens, Hyeon Kim, Reece Wagstaff, Shengbin Li, H. Abdelaal, Nathan Kemp, D. Watkins, S. MaWhinney, P. Skinner (2014)
Compartmentalization of Simian Immunodeficiency Virus Replication within Secondary Lymphoid Tissues of Rhesus Macaques Is Linked to Disease Stage and Inversely Related to Localization of Virus-Specific CTLThe Journal of Immunology, 193
P. Denton, Julie Long, S. Wietgrefe, C. Sykes, Rae Spagnuolo, Olivia Snyder, K. Perkey, N. Archin, S. Choudhary, Kuo Yang, M. Hudgens, I. Pastan, A. Haase, A. Kashuba, E. Berger, D. Margolis, J. Garcia, D. Douek (2014)
Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ARTPLoS Pathogens, 10
W. Winnall, Matthew Beasley, R. Center, M. Parsons, Ben Kiefel, S. Kent (2014)
The maturation of antibody technology for the HIV epidemicImmunology and Cell Biology, 92
R. Mitsuyasu, P. Anton, S. Deeks, D. Scadden, E. Connick, Matthew Downs, A. Bakker, M. Roberts, C. June, S. Jalali, A. Lin, R. Pennathur-das, K. Hege (2000)
Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.Blood, 96 3
C. Lamers, R. Willemsen, P. Elzakker, Sabine Steenbergen-Langeveld, M. Broertjes, J. Oosterwijk-Wakka, E. Oosterwijk, S. Sleijfer, R. Debets, J. Gratama (2011)
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.Blood, 117 1
O. Yang, Tran Ac, Spyros Kalams, R. Johnson, Roberts Mr, B. Walker (1997)
Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.Proceedings of the National Academy of Sciences of the United States of America, 94 21
S. Deeks, Bridget Wagner, P. Anton, R. Mitsuyasu, D. Scadden, Christine Huang, C. Macken, D. Richman, C. Christopherson, C. June, R. Lazar, D. Broad, S. Jalali, K. Hege (2002)
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.Molecular therapy : the journal of the American Society of Gene Therapy, 5 6
Y. Fukazawa, Haesun Park, M. Cameron, F. Lefebvre, R. Lum, Noel Coombes, Eisa Mahyari, S. Hagen, Jin Bae, Marcelo Reyes, Tonya Swanson, Alfred Legasse, A. Sylwester, S. Hansen, Andrew Smith, Petra Stafova, R. Shoemaker, Yuan Li, K. Oswald, M. Axthelm, A. McDermott, G. Ferrari, D. Montefiori, P. Edlefsen, M. Piatak, J. Lifson, R. Sékaly, L. Picker (2012)
Lymph node T cell responses predict the efficacy of live attenuated SIV vaccinesNature medicine, 18
J. Sacha, C. Chung, E. Rakasz, S. Spencer, A. Jonas, Alexander Bean, Wonhee Lee, B. Burwitz, Jason Stephany, J. Loffredo, D. Allison, Sama Adnan, A. Hoji, N. Wilson, T. Friedrich, J. Lifson, O. Yang, D. Watkins (2007)
Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression1The Journal of Immunology, 178
K. Rainwater-Lovett, K. Luzuriaga, D. Persaud (2015)
Very early combination antiretroviral therapy in infants: prospects for cureCurrent Opinion in HIV and AIDS, 10
Y. Fukazawa, R. Lum, A. Okoye, Haesun Park, K. Matsuda, Jin Bae, S. Hagen, R. Shoemaker, C. Deleage, Carissa Lucero, D. Morcock, Tonya Swanson, Alfred Legasse, M. Axthelm, J. Hesselgesser, R. Geleziunas, V. Hirsch, P. Edlefsen, M. Piatak, J. Estes, J. Lifson, L. Picker (2014)
A B cell follicle sanctuary permits persistent productive SIV infection in elite controllersNature medicine, 21
M. Perreau, A. Savoye, E. Crignis, J. Corpataux, R. Cubas, E. Haddad, L. Leval, C. Graziosi, G. Pantaleo (2013)
Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and productionThe Journal of Experimental Medicine, 210
Xueling Wu, Charlene Wang, S. O'dell, Yuxing Li, B. Keele, Zhongjia Yang, H. Imamichi, N. Doria-Rose, J. Hoxie, M. Connors, G. Shaw, R. Wyatt, J. Mascola (2012)
Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding SiteJournal of Virology, 86
S. Yukl, E. Boritz, M. Busch, Christopher Bentsen, T. Chun, D. Douek, Evelyn Eisele, A. Haase, Ya Ho, G. Hütter, J. Justement, S. Keating, Tzong-Hae Lee, Peilin Li, D. Murray, S. Palmer, C. Pilcher, S. Pillai, R. Price, M. Rothenberger, T. Schacker, J. Siliciano, R. Siliciano, R. Siliciano, E. Sinclair, M. Strain, J. Wong, D. Richman, S. Deeks (2013)
Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin PatientPLoS Pathogens, 9
Authors Fisher, Yegor Voronin, R. Jefferys (2014)
Therapeutic HIV vaccines: prior setbacks, current advances, and future prospects.Vaccine, 32 43
Jacqueline Corrigan‐Curay, H. Kiem, D. Baltimore, Marina O’reilly, R. Brentjens, L. Cooper, S. Forman, S. Gottschalk, P. Greenberg, R. Junghans, H. Heslop, M. Jensen, C. Mackall, C. June, O. Press, D. Powell, A. Ribas, S. Rosenberg, M. Sadelain, B. Till, A. Patterson, R. Jambou, E. Rosenthal, L. Gargiulo, Maureen Montgomery, D. Kohn (2014)
T-cell immunotherapy: looking forward.Molecular therapy : the journal of the American Society of Gene Therapy, 22 9
Kristina Allers, Gero Hütter, Jörg Hofmann, Christoph Loddenkemper, Kathrin Rieger, Eckhard Thiel, Thomas Schneider (2011)
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.Blood, 117 10
C. Romeo, B. Seed (1991)
Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptidesCell, 64
R. Mazor, Jaime Eberle, Xiaobo Hu, A. Vassall, M. Onda, R. Beers, Elizabeth Lee, R. Kreitman, Byungkook Lee, D. Baker, C. King, R. Hassan, I. Benhar, I. Pastan (2014)
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesProceedings of the National Academy of Sciences, 111
U. Military, W. Reed (2014)
How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs ?
S. Masiero, C. Vecchio, R. Gavioli, G. Mattiuzzo, M. Cusi, Lucia Micheli, F. Gennari, A. Siccardi, W. Marasco, G. Palù, C. Parolin (2005)
T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120Gene Therapy, 12
CE: Namrta; COH/100311; Total nos of Pages: 7; COH 100311 REVIEW URRENT Toward an HIV cure based on targeted killing PINION of infected cells: different approaches against acute versus chronic infection Barna Dey and Edward A. Berger Purpose of review Current regimens of combination antiretroviral therapy (cART) offer effective control of HIV infection, with maintenance of immune health and near-normal life expectancy. What will it take to progress beyond the status quo, whereby infectious virus can be eradicated (a ‘sterilizing cure’) or fully controlled without the need for ongoing cART (a ‘functional cure’)? Recent findings On the basis of therapeutic advances in the cancer field, we propose that targeted cytotoxic therapy to kill HIV-infected cells represents a logical complement to cART for achieving an HIV cure. This concept is based on the fact that cART effectively blocks replication of the virus, but does not eliminate cells that are already infected; targeted cytotoxic therapy would contribute precisely this missing component. We suggest that different modalities are suited for curing primary acute versus established chronic infection. For acute infection, relatively short-acting potent agents such as recombinant immunotoxins might prove sufficient for HIV eradication, whereas for chronic infection, a long-lasting (lifelong?) modality
Current Opinion in HIV and Aids – Wolters Kluwer Health
Published: Feb 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.